- Division of Basic and Integrative Biological Sciences – DBIB
- Review Branch:
- Macromolecular Biophysics and Biological Chemistry – MBBC
- Study Section:
- Chemical Biology & Probes – CBP
Dr. Mike Eissenstat received his Ph.D. in organic chemistry from Harvard University and did postdoctoral work in organic synthesis at the University of Pittsburgh. He then joined Sterling Drug as a medicinal chemist, where he worked in many therapeutic areas and was co-project leader of the analgesics project team. He subsequently joined the Structural Biochemistry Program of SAIC at NCI-Frederick where he worked on structure-based drug design of HIV protease and other aspartyl protease inhibitors. Then, after a brief stint at Tibotec Inc. as Associate Director, he helped found Sequoia Pharmaceuticals. As the Vice President of Chemistry at Sequoia, his team discovered the HIV protease inhibitor SPI-256 and the PK enhancer SPI-452, both compounds have completed Phase 1 clinical trials.